CohBar is a clinical stage biotechnology company utilizing the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. In addition, Co. has multiple preclinical programs, such as a program in acute respiratory distress syndrome as well as earlier stage discovery programs. Co.'s pipelines include: CB5138-3, which is for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases; CB4211, which is for the treatment of nonalcoholic steatohepatitis and obesity; and CB5064 Analogs, family of peptides that are agonists of the apelin receptor. The CWBR YTD return is shown above.
The YTD Return on the CWBR YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CWBR YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CWBR YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|